Compare RR & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RR | IMMX |
|---|---|---|
| Founded | 2016 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 614.9M | 716.2M |
| IPO Year | 2023 | 2021 |
| Metric | RR | IMMX |
|---|---|---|
| Price | $1.57 | $8.60 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.00 | ★ $19.20 |
| AVG Volume (30 Days) | ★ 7.5M | 2.1M |
| Earning Date | 05-13-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,045,000.00 | N/A |
| Revenue This Year | $75.68 | N/A |
| Revenue Next Year | $78.28 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 18.99 | N/A |
| 52 Week Low | $1.53 | $1.94 |
| 52 Week High | $7.43 | $12.14 |
| Indicator | RR | IMMX |
|---|---|---|
| Relative Strength Index (RSI) | 31.99 | 39.80 |
| Support Level | $1.53 | $7.99 |
| Resistance Level | $2.21 | $9.37 |
| Average True Range (ATR) | 0.09 | 0.90 |
| MACD | 0.01 | -0.28 |
| Stochastic Oscillator | 4.63 | 1.93 |
Richtech Robotics Inc is a robotics and artificial intelligence (AI) technology company focused on developing embodied AI systems that aims to improve the efficiency and productivity of businesses. The company trains proprietary artificial intelligence models on in-house data to operate robotic systems in the real world. It designs, engineers, manufactures, and deploys next generation embodied AI systems to serve a wide range of industries, including food service, retail, industrial manufacturing, automotive, healthcare, and hospitality. The company's offerings include Commercial Robotic Products, Industrial Robotic Products and Data Services. The company generated the majority of its revenue through product revenue (i.e. outright hardware sales).
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.